Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genscript Biotech ( (HK:1548) ).
Genscript Biotech has called its 2026 annual general meeting for 5 June 2026 in Jiangning District, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025. They will also consider the re-election of four directors, the authorization of board discretion on director remuneration, and the re-appointment of Ernst & Young as auditor with the board empowered to set audit fees.
In addition to routine governance items, the AGM will ask shareholders to grant the board a broad mandate to issue, allot, or otherwise deal with additional shares, including treasury shares, and related convertible securities and options within defined limits. This share issuance authority, if approved, would enhance the company’s financial and strategic flexibility, potentially supporting future capital raising, incentive plans, and corporate transactions that could influence ownership structure and shareholder value.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$15.50 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a biotechnology company listed in Hong Kong that operates through subsidiaries and focuses on life sciences and related biotechnological services. The company is incorporated in the Cayman Islands with limited liability and is regulated under the Listing Rules of the Hong Kong Stock Exchange.
YTD Price Performance: 3.14%
Average Trading Volume: 9,099,847
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.88B
See more data about 1548 stock on TipRanks’ Stock Analysis page.